Pharma Industry Enters the Era of 'Precision Acquisitions' with Multiple Deals Closed This Week

　　【Pharmaceutical Network - Industry Dynamics] Since 2026, pharmaceutical companies both domestically and internationally have engaged in intensive acquisition activities. This week, several pharmaceutical firms actively acquired innovative companies possessing cutting-edge technology platforms (such as mRNA and complex formulations) to rapidly bolster their pipelines and achieve business upgrades or transformations.
 

On January 28, Kanghua Biological announced that it had signed an Investment Letter of Intent with NanoRibo and certain of its existing shareholders. Under the agreement, Kanghua Biological will subscribe for NanoRibo’s increased registered capital in installments and acquire equity interests held by NanoRibo’s existing shareholders. Specifically, Kanghua Biological intends to initially subscribe for NanoRibo’s increased registered capital at a consideration not exceeding RMB 120 million, thereby acquiring a 27.27% stake upon completion. The remaining equity interests will be acquired in stages based on subsequent research and development milestones.
 

Kanghua Biologics is a biopharmaceutical company engaged in the research and development, production, and sales of biological products. Its current product portfolio includes the “ACYW135 Group Meningococcal Polysaccharide Vaccine” (brand name: Maikexin®) and the “Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)” (brand name: HDCV®). This acquisition aims to enhance its mRNA technology platform and enrich its R&D pipeline. It is reported that NanoRibo’s independently developed lyophilized respiratory syncytial virus (RSV) mRNA vaccine has currently entered Phase I clinical trials.
 

January 28 News: KingMed Diagnostics Gene Technology Co., Ltd. announced that it has completed the acquisition of a 90% equity stake in Shanghai Zhengu Biotechnology Co., Ltd. It is understood that since its establishment, Zhengu Biotechnology has consistently focused on the field of companion diagnostics. Leveraging its proprietary SLIMamp® ultra-high multiplex amplification library preparation technology, the company has developed a comprehensive end-to-end solution featuring “one-tube library preparation and one-click analysis.” Furthermore, it has achieved regulatory approval breakthroughs in colorectal cancer (CRC), a high-incidence malignancy.
 

Regarding this acquisition, Kingstar Global stated that it represents a critical step in the company’s evolution from a leader in hematologic diseases to a comprehensive oncology platform. This move will not only strengthen its technical capabilities in companion diagnostics but also further refine its business layout in solid tumors, creating a new growth curve beyond its hematology specialty.
 

In fact, Kingstar Global has been accelerating its layout in the field of precision diagnosis and treatment for solid tumors in recent years, having strategically acquired a controlling stake in Guangzhou Basecare Medical in 2024. This transaction marks Kingstar Global’s formal establishment of a complete business closed loop covering three core segments: early cancer screening and diagnosis, companion diagnostics, and recurrence monitoring (MRD).
 

In addition to domestic pharmaceutical companies, foreign pharmaceutical firms have also shown strong enthusiasm for acquisitions in recent days. On January 29, Repare Therapeutics Inc. announced that the previously disclosed acquisition of all its issued and outstanding common shares by the non-profit biotechnology company XenoTherapeutics, Inc. and Xeno Acquisition Corp., through a statutory arrangement plan, had been completed.
 

January 28 News: Boston Scientific Announces Completion of Nalu Medical Acquisition, Formally Integrating It into Its Neuromodulation Business. It is reported that Boston Scientific became a strategic investor in Nalu Medical in 2017 and ultimately launched the acquisition of Nalu Medical for $600 million six years after the launch of Nalu Medical’s miniaturized chronic pain stimulator, Nalu. In addition, biopharmaceutical company Halozyme has recently expanded its drug delivery business through the acquisition of Surf Bio. Reportedly, this transaction includes a $300 million upfront payment and up to $100 million in potential milestone payments.
 

Overall, the pharmaceutical industry has entered an era of “precision M&A” in 2026, with technology-platform biotech companies, high-growth sector assets, and overseas distribution channels becoming hot acquisition targets. Industry experts believe that such mergers and acquisitions will accelerate industry consolidation, drive resource concentration toward market leaders, and promote technological integration and global expansion.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.